Vitiligo

Andrew Alexis, MD, MPH, reviews the case of a 66-year-old woman who presented with depigmented patches and provides clinical insights on barriers typically encountered during the management of this condition.

An expert on vitiligo discusses the case of a 49-year-old woman with a history of vitiligo who presents with depigmented macules on her abdomen, thighs, and forearms that developed over 2 months.

Andrew Alexis, MD, MPH, presents the case of a 60-year-old man with a 5-year history of vitiligo who received topical ruxolitinib 1.5% cream and achieved gradual repigmentation over a six-month period.

David Rosmarin, MD, shared his insights on the study in a Q&A with Dermatology Times.

Silverberg discusses her SPD 2024 lecture, "Approach to Progressive Vitiligo," the future vitiligo landscape, and more.

Dr. Latanya Benjamin, MD, FAAD, FAAP, discusses the role of topical ruxolitinib cream in managing vitiligo and its effectiveness in a 25-year-old female patient.

A pediatric dermatologist reviews the case of a 25-year-old female with a history of vitiligo since adolescence who is affected by the social stigma of the condition.

Dr. Latanya Benjamin, MD, FAAD, FAAP, continues her discussion on a 35-year-old female patient with vitiligo by analyzing laboratory workup results and exploring advanced treatment decisions to optimize patient outcomes.

Highlighting the emotional impact of vitiligo on patients, Latanya Benjamin, MD, FAAD, FAAP, presents the case of a 35-year-old female patient with growing depigmentation in highly visible areas.

Walter Liszewski, MD, shares insights into discrepancies between permanent makeup and decorative tattoos and which patients may benefit from permanent makeup.

Continuing the discussion of a 50-year-old male patient with vitiligo, Anthony Nuara, MD, PhD, addresses the intricacies of treating patients who have relapsed or experienced a loss of efficacy following their initial treatment and highlights how to select 2nd line treatments with greater efficacy.

An expert on the treatment of vitiligo reviews a second patient case, a 50-year-old male patient who regularly wears medical gloves for his work and whose development of well-defined white patches on his fingers and toes prompted treatment.

Anthony Nuara, MD, PhD, presents the case of a 32-year-old woman with vitiligo, covering her initial diagnosis and workup findings, ending this segment with her prescribed treatments and how shared decision-making lead to these choices.

The treatment of vitiligo has advanced from ancient herbal remedies to the first FDA-approved topical, paving the way for improved management and outcomes.

In today’s podcast, Silverberg discusses topical therapeutics for vitiligo and clinical excellence.

The study found that CMT is effective and well-tolerated in treating stable vitiligo, with significant positive correlations between the target area treatment ratio and repigmentation.

Researchers stated the findings highlight the need for integrated dermatological and psychological treatment approaches.

The study found a genetic link between vitiligo and autoimmune thyroid diseases, but no similar link with autoimmune hepatitis or Graves' disease.

Conversely, there were higher levels of selenium and folic acid detected in patients with vitiligo versus otherwise healthy individuals.

The study found patients with vitiligo are at a lower risk of developing PD, but those with comorbid PD could face elevated mortality rates.

David Rosmarin, MD, shares key points from phase 3 data of ruxolitinib for vitiligo, as well as highlights the potential for targeting the STAT pathway in upcoming atopic dermatitis therapeutics.

Karan Lal, DO, dives into the benefits of combination therapy for vitiligo with topicals and devices.

Nanette Silverberg, MD, shares data on the efficacy of on- and off-label therapeutics for vitiligo, as well as the importance of communication with patients to promote clinical excellence.

Data from the TRuE-V mechanism of action study was presented in a poster at the 2024 RAVE Conference.

Nanette Silverberg, MD, shares her excitement about the inclusion of vitiligo at this year’s RAVE meeting.